ABIGAIL BURKE: Open Payments
NPI 1487387866 · SHERIDAN, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$409 in 22 payments from 11 companies in 2025. Trend: 2023 $680 · 2024 $977 · 2025 $409
Food & beverage: $409
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 5 | $96 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $70 |
| ABBVIE INC. | 3 | $66 |
| AstraZeneca Pharmaceuticals LP | 3 | $45 |
| GlaxoSmithKline, LLC. | 2 | $29 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $21 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $21 |
| Amgen Inc. | 1 | $17 |
| PFIZER INC. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
Products named: CAPLYTA, VRAYLAR, Ozempic, AIRSUPRA, SHINGRIX, Kerendia, XIFAXAN, UBRELVY.
Industry payments across IN — which companies pay providers there.
